Prevalence of hepatitis E virus and reassessment of HIV and other hepatitis virus seroprevalences among French prison inmates.
Adolescent
Adult
Aged
Coinfection
Female
HIV Antibodies
/ immunology
HIV Infections
/ epidemiology
Hepatitis Antibodies
/ immunology
Hepatitis E
/ epidemiology
Hepatitis E virus
/ immunology
Hepatitis Viruses
/ immunology
Hepatitis, Viral, Human
/ epidemiology
Humans
Male
Middle Aged
Prevalence
Prisoners
Prospective Studies
Public Health Surveillance
Seroepidemiologic Studies
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
01
2019
accepted:
03
06
2019
entrez:
27
6
2019
pubmed:
27
6
2019
medline:
19
2
2020
Statut:
epublish
Résumé
Prison inmates are considered a high-risk population for blood-borne and enterically transmitted infections before and during their imprisonment. Hepatitis E virus (HEV) prevalence is unknown among French inmates, whereas a reassessment of human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) prevalences is required to describe the epidemiologic evolution in this high-risk population. A prospective survey was conducted from June to December 2017 in Fresnes prison, a penitentiary center with 2,581 inmates. In addition to HIV, HAV, HBV and HCV testing, which is offered to all patients at admission, we systematically offered HEV screening. Retrospective serological data for HIV, HBV and HCV, collected annually from 2014 to 2017, were also used to assess evolution. In 2017, 1,093 inmates were screened for HEV, HIV, HAV, HBV and HCV. Prevalences in this population were 8.2%, 1.3%, 62.7%, 1.9% and 2.9%, respectively. HEV seroprevalence increased with age (p<0.0001) and was higher among Eastern Europe born inmates (p<0.0001). Between 2014 and 2017, HIV seroprevalence remained steady, while a decrease in HBV and HCV seroprevalence was observed. Compared to the reported prevalence in French blood donors, HEV seroprevalence was remarkably low in French inmates. HIV, HAV, HBV and HCV prevalences among prisoners were higher than reported in the general population.
Sections du résumé
BACKGROUND
Prison inmates are considered a high-risk population for blood-borne and enterically transmitted infections before and during their imprisonment. Hepatitis E virus (HEV) prevalence is unknown among French inmates, whereas a reassessment of human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) prevalences is required to describe the epidemiologic evolution in this high-risk population.
METHODS
A prospective survey was conducted from June to December 2017 in Fresnes prison, a penitentiary center with 2,581 inmates. In addition to HIV, HAV, HBV and HCV testing, which is offered to all patients at admission, we systematically offered HEV screening. Retrospective serological data for HIV, HBV and HCV, collected annually from 2014 to 2017, were also used to assess evolution.
RESULTS
In 2017, 1,093 inmates were screened for HEV, HIV, HAV, HBV and HCV. Prevalences in this population were 8.2%, 1.3%, 62.7%, 1.9% and 2.9%, respectively. HEV seroprevalence increased with age (p<0.0001) and was higher among Eastern Europe born inmates (p<0.0001). Between 2014 and 2017, HIV seroprevalence remained steady, while a decrease in HBV and HCV seroprevalence was observed.
CONCLUSIONS
Compared to the reported prevalence in French blood donors, HEV seroprevalence was remarkably low in French inmates. HIV, HAV, HBV and HCV prevalences among prisoners were higher than reported in the general population.
Identifiants
pubmed: 31242210
doi: 10.1371/journal.pone.0218482
pii: PONE-D-19-02837
pmc: PMC6594613
doi:
Substances chimiques
HIV Antibodies
0
Hepatitis Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218482Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Public Health. 2015 Oct 27;15:1093
pubmed: 26507505
J Med Virol. 2010 Apr;82(4):546-55
pubmed: 20166185
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
J Gen Virol. 2001 May;82(Pt 5):1001-1012
pubmed: 11297675
Viruses. 2016 Aug 06;8(8):
pubmed: 27509518
Euro Surveill. 2013 Jul 11;18(28):
pubmed: 23870097
BMJ Open. 2014 Oct 19;4(10):e005694
pubmed: 25331969
BMC Public Health. 2010 Dec 21;10:777
pubmed: 21176146
Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):479-485
pubmed: 27785638
Braz J Infect Dis. 2011 May-Jun;15(3):272-5
pubmed: 21670930
BMC Infect Dis. 2018 Feb 12;18(1):79
pubmed: 29433454
Infection. 2013 Feb;41(1):69-76
pubmed: 23264095
Hepatology. 2016 Apr;63(4):1145-54
pubmed: 27008201
Eur J Public Health. 2016 Feb;26(1):122-8
pubmed: 26454876